TY - JOUR
T1 - Low Dose Recombinant Interferon Alfa Treatment for Classic Kaposi's Sarcoma
AU - Tur, Ethel
AU - Brenner, Sarah
AU - Michalevicz, Rita
PY - 1993/10
Y1 - 1993/10
N2 - Background: High doses of interferon alfa are used to treat Kaposi's sarcoma in patients with immunodeficiency, whereas low doses are generally ineffective. Following low-dose recombinant interferon alfa treatment for lymphoma, two patients showed a regression of their hematologic malignancy-associated Kaposi's sarcoma. This observation prompted us also to try lowdose interferon alfa treatment in uncomplicated classic Kaposi's sarcoma, and two additional patients were thus treated on an outpatient basis. Observations: Initial response was noted after 3 to 13 weeks of treatment. Remission was achieved after 4 to 6 months of low-dose interferon alfa treatment and its duration was 8 to 14 months. Recurrences were treated again and additional remissions were obtained after only 5 to 8 weeks of treatment. Conclusion: Low-dose interferon alfa treatment may represent an effective therapeutic modality for the treatment of patients with both lymphoma-associated and uncomplicated classic Kaposi's sarcoma.
AB - Background: High doses of interferon alfa are used to treat Kaposi's sarcoma in patients with immunodeficiency, whereas low doses are generally ineffective. Following low-dose recombinant interferon alfa treatment for lymphoma, two patients showed a regression of their hematologic malignancy-associated Kaposi's sarcoma. This observation prompted us also to try lowdose interferon alfa treatment in uncomplicated classic Kaposi's sarcoma, and two additional patients were thus treated on an outpatient basis. Observations: Initial response was noted after 3 to 13 weeks of treatment. Remission was achieved after 4 to 6 months of low-dose interferon alfa treatment and its duration was 8 to 14 months. Recurrences were treated again and additional remissions were obtained after only 5 to 8 weeks of treatment. Conclusion: Low-dose interferon alfa treatment may represent an effective therapeutic modality for the treatment of patients with both lymphoma-associated and uncomplicated classic Kaposi's sarcoma.
UR - http://www.scopus.com/inward/record.url?scp=0027363982&partnerID=8YFLogxK
U2 - 10.1001/archderm.1993.01680310067011
DO - 10.1001/archderm.1993.01680310067011
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:0027363982
SN - 0003-987X
VL - 129
SP - 1297
EP - 1300
JO - Archives of Dermatology
JF - Archives of Dermatology
IS - 10
ER -
